InMed Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Lead drug INM-901 showed strong preclinical efficacy in Alzheimer's models, reducing neuroinflammation and improving cognition, with a pre-IND FDA meeting planned for Q3 and clinical trials targeted for 2027. INM-089 and INM-755 also advance in eye and skin disease, supported by robust IP and a $7M cash position.
Fiscal Year 2025
-
The presentation highlighted progress on proprietary drug candidates targeting neuroinflammation and neuroprotection for Alzheimer's and dry AMD, with INM-901 prioritized for its promising preclinical results. Financially stable, the company seeks strategic partners to accelerate development and expects key catalysts in 2026.
-
Three drug candidates are advancing, with INM-901 for Alzheimer's and INM-089 for dry AMD showing promising preclinical results and moving toward FDA pre-IND meetings next year. The commercial arm remains profitable, and the company is well-funded through 2026, focusing on partnerships and further clinical progress.
-
Presentations highlighted a robust pipeline targeting Alzheimer's, dry AMD, and dermatology, with INM-901 showing promising preclinical results. Profitable commercial operations support R&D, and strategic partnerships are being pursued to accelerate clinical progress.
Fiscal Year 2024
-
Alzheimer's research is rapidly advancing, with new disease-modifying therapies, improved biomarker-driven patient selection, and a growing focus on neuroinflammation as a therapeutic target. Precision medicine and combination therapies are expected to transform Alzheimer's into a manageable chronic disease.
-
The company is advancing three drug candidates, with INM-901 for Alzheimer's showing promising preclinical results and INM-089 targeting dry AMD. Profitable subsidiary BayMedica supports operations, and long-term animal data for Alzheimer's is expected soon.